Upregulated CCL20 and CCR6 in Cancer Stem Cells Converted from Mouse iPS Cells

Background: Cancer stem cells (CSCs) as a class of malignant cancer cells play an important role in tumor progression. Previous studies by our group have demonstrated the establishment of the model of CSCs converting mouse iPS cells (miPSCs) into CSCs by treating the miPSCs with a conditioned medium (CM) of Lewis Lung Carcinoma (LLC) cells with or without the nonmutagenic chemical compounds. CSCs converted from miPSCs developed highly malignant adenocarcinoma when subcutaneously transplanted into the nude mice. Methods: The miPSCs were treated with each compound for 1 week in the presence of a CM of LLC cells. We evaluated the gene expression in the resultant CSCs comparing that in miPSCs by microarray analysis. And the expression of chemokine (C-C motif) ligand 20 (CCL20) and C-C chemokine receptor type 6 (CCR6) in converted cells were evaluated by rt-qPCR. The CCR6 expression in converted cells and primary cells were determined by flow cytometry. Results: As the result, the expression of CCL20 was found upregulated in the presence of CM supplemented with PD0325901. Then we assessed the expression of CCR6, which was considered to be stimulated by CCL20. Then the expression of CCR6 was also found up-regulated. Interestingly, IL17A expression was also observed only in the CSCs from the primary tumor implying the effect of tumor microenvironment. Moreover, significantly high level of CCR6 was showed in flow cytometric analysis. Conclusion: These results suggest that a model of CSCs with CCL20-CCR6 autocrine loop was obtained as the result of the conversion of iPSCs. This CSC should be a good model to study targeting CCR6 as a G protein-coupled receptor (GPCR).

[1]  M. Seno,et al.  A cancer stem cell model as the point of origin of cancer-associated fibroblasts in tumor microenvironment , 2017, Scientific Reports.

[2]  M. Seno,et al.  A new PDAC mouse model originated from iPSCs-converted pancreatic cancer stem cells (CSCcm). , 2016, American journal of cancer research.

[3]  M. Seno,et al.  Characterization of Gene Expression Patterns among Artificially Developed Cancer Stem Cells Using Spherical Self-Organizing Map , 2016, Cancer informatics.

[4]  Li-hua Shang,et al.  Interleukin-17 promotes angiogenesis by stimulating VEGF production of cancer cells via the STAT3/GIV signaling pathway in non-small-cell lung cancer , 2015, Scientific Reports.

[5]  Li-hua Shang,et al.  Interleukin-17 levels correlate with poor prognosis and vascular endothelial growth factor concentration in the serum of patients with non-small cell lung cancer , 2015, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[6]  Y. Iwakura,et al.  Exacerbation of experimental autoimmune encephalomyelitis in mice deficient for DCIR, an inhibitory C-type lectin receptor , 2014, Experimental animals.

[7]  M. Hendrix,et al.  A Model of Cancer Stem Cells Derived from Mouse Induced Pluripotent Stem Cells , 2012, PloS one.

[8]  A. Peled,et al.  Involvement of CCR6/CCL20/IL-17 Axis in NSCLC Disease Progression , 2011, PloS one.

[9]  F. André,et al.  Expression of chemokine receptor CCR6 as a molecular determinant of adrenal metastatic relapse in patients with primary lung cancer. , 2010, Clinical lung cancer.

[10]  D. Aebersold,et al.  The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer , 2009, International journal of cancer.

[11]  Jeffrey M. Rosen,et al.  The Increasing Complexity of the Cancer Stem Cell Paradigm , 2009, Science.

[12]  M. Seno,et al.  Spherical self-organizing map as a helpful tool to identify category-specific cell surface markers. , 2008, Biochemical and biophysical research communications.

[13]  B. Doble,et al.  The ground state of embryonic stem cell self-renewal , 2008, Nature.

[14]  J. O’Shea,et al.  Th17 cells: a new fate for differentiating helper T cells , 2008, Immunologic research.

[15]  L. Cosmi,et al.  Phenotypic and functional features of human Th17 cells , 2007, The Journal of experimental medicine.

[16]  M. Parmentier,et al.  Expression of the chemokine receptor CCR6 in the Lewis lung carcinoma (LLC) cell line reduces its metastatic potential in vivo , 2007, Cancer Gene Therapy.

[17]  T. Ichisaka,et al.  GENERATION OF GERMLINECOMPETENT INDUCED PLURIPOTENT STEM CELLS , 2007 .

[18]  P. McCray,et al.  CCL20 is an inducible product of human airway epithelia with innate immune properties. , 2003, American journal of respiratory cell and molecular biology.

[19]  Á. Zaballos,et al.  Molecular cloning, functional characterization and mRNA expression analysis of the murine chemokine receptor CCR6 and its specific ligand MIP‐3α 1 , 1998 .

[20]  M. Baggiolini.  Chemokines and leukocyte traffic , 1998, Nature.

[21]  S. Ullrich,et al.  STRL22 is a receptor for the CC chemokine MIP-3alpha. , 1997, Biochemical and biophysical research communications.

[22]  H. Nomiyama,et al.  Identification of CCR6, the Specific Receptor for a Novel Lymphocyte-directed CC Chemokine LARC* , 1997, The Journal of Biological Chemistry.